Neoadjuvant Chemoradiotherapy for Stage II or III Esophageal Squamous Cell Carcinoma.
Anticancer Res
; 37(6): 3301-3306, 2017 06.
Article
in En
| MEDLINE
| ID: mdl-28551681
ABSTRACT
BACKGROUND/AIM:
The goal of this retrospective study was to investigate the efficacy and safety of neoadjuvant chemoradiotherapy (CRT) in patients with Stage II or Stage III esophageal squamous cell carcinoma (SCC). PATIENTS ANDMETHODS:
Between January 2004 and December 2014, a total of 86 patients underwent surgical resection in conjunction with preoperative CRT for esophageal SCC in our Institute.RESULTS:
A pathological complete response was achieved in 38.7% of patients with Stage II cancer and 20% of patients with Stage III. Postoperative complications were observed in 61.3% of Stage II and 76.4% of Stage III patients. The 5-year overall survival rate (OS) was 83.2% in Stage II and 22.8% in Stage III (p=0.0001). The 5-year disease-free survival (DFS) rate was 67.9% in Stage II and 29.9% in Stage III (p=0.0007).CONCLUSION:
Neoadjuvant CRT may improve OS and DFS rates in patients with Stage II esophageal SCC.Key words
Search on Google
Database:
MEDLINE
Main subject:
Esophageal Neoplasms
/
Carcinoma, Squamous Cell
/
Esophagectomy
/
Neoadjuvant Therapy
/
Chemoradiotherapy, Adjuvant
Type of study:
Etiology_studies
/
Observational_studies
/
Prognostic_studies
/
Risk_factors_studies
Limits:
Adult
/
Aged
/
Aged80
/
Female
/
Humans
/
Male
/
Middle aged
Language:
En
Journal:
Anticancer Res
Year:
2017
Type:
Article
Affiliation country:
Japan